title: [Tamoxifen; wider indications, more frequent controls?].
authors.forename: M J
authors.initials: MJ
authors.lastname: Mourits
authors.forename: A G
authors.initials: AG
authors.lastname: van der Zee
authors.forename: P H
authors.initials: PH
authors.lastname: Willemse
authors.forename: E G
authors.initials: EG
authors.lastname: de Vries
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D005260:Female; D006801:Humans; D009426:Netherlands; D010048:Ovarian Cysts / Q000139:chemically induced / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D017697:Premenopause; D013629:Tamoxifen / Q000009:adverse effects*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen